Loading market dashboard
Indivior Pharmaceuticals Inc
INDVHealthcareNASDAQUS
Loading disclosure news
News and disclosures filtered by period, publisher, and event group.
Select a headline to open the full news page in the app.
INDV, RNW, LCUT, NTCT and TNK passed a screen for efficiency, outperforming industry peers on inventory, receivables, assets and margins.
Indivior develops buprenorphine-based treatments for opioid dependence, serving markets in the US, UK, and worldwide.
Indivior develops buprenorphine-based therapies for opioid dependence, serving healthcare providers and treatment centers worldwide.
RICHMOND, Va., May 20, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc., (Nasdaq: INDV) today announced findings from two new real-world evidence studies showing that adherence to extended-release buprenorphine, a monthly injectable commercially available as SUBLOCADE®, is associated with lower relapse risk, fewer infection-related complications, and reduced healthcare utilization among people living with opioid use disorder (OUD). “Collectively, these studies highlight the benefits of sustained treatment with monthly injectable buprenorphine, including reduced relapse risk and fewer serious complications that often drive acute care use,” said Christian Heidbreder, Ph.D., Chief Scientific Officer at Indivior. “These findings also emphasize the importance of proactively identifying patients at risk of treatment discontinuation and supporting continued access to evidence‑based medications for opioid use disorder.”
Indivior Pharmaceuticals Inc. (INDV) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
RICHMOND, Va., May 14, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc. (Nasdaq: INDV) today announced that it will participate in the following upcoming investor conferences: 2026 Jefferies Global Healthcare Conference – New York, NY – June 3 rd Joe Ciaffoni, Chief Executive Officer, and Ryan Preblick, Chief Financial Officer, will host 1x1 / group meetings on Wednesday, June 3rd and will also participate in a fireside chat on Wednesday, June 3rd at 11:05 a.m.
Indivior develops proprietary treatments for opioid dependence, generating revenue from specialty pharmaceuticals across global markets.
COCO, INDV and MPC stand out as momentum buys as investors apply Richard Driehaus' "buy high and sell higher" strategy.
Does Indivior Pharmaceuticals Inc. (INDV) have what it takes to be a top stock pick for momentum investors? Let's find out.
Indivior Pharmaceuticals Inc. (INDV) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
INDV, NVT and AVT made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on May 5, 2026.
RICHMOND, Va., May 04, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc. (Nasdaq: INDV), today announced that it has entered into a $175 million accelerated share repurchase agreement (“the ASR”) with Barclays Bank PLC (“Barclays”).
Indivior Pharmaceuticals, Inc. (INDV) Q1 2026 Earnings Call Transcript
Indivior Pharmaceuticals Inc. (INDV) came out with quarterly earnings of $0.96 per share, beating the Zacks Consensus Estimate of $0.64 per share. This compares to earnings of $0.41 per share a year ago.
Q1'26 Total Net Revenue of $317 Million, Up 19% YoY Q1'26 Total SUBLOCADE® Net Revenue of $232 Million, Up 32% YoY Q1'26 GAAP Net Income of $89 Million and Q1'26 Non-GAAP Net Income of $123 Million Record Quarterly Adjusted EBITDA of $164 Million in Q1'26, Up 112% YoY Repurchased Approximately Four Million Shares in Q1'26 for $125 Million Conference Call at 8:00 A.M. EDT Today RICHMOND, Va.
If you're interested in broad exposure to the Small Cap Blend segment of the US equity market, look no further than the Invesco Russell 2000 Dynamic Multifactor ETF (OMFS), a passively managed exchange traded fund launched on November 8, 2017.
Novartis secures CHMP backing for Itvisma in SMA and wins WHO nod for Coartem Baby, targeting critical gaps in rare disease and infant malaria care.
A collaboration with Virginia Tech supports recognizing remission as a treatment outcome-capturing symptoms, quality of life, and functional outcomes-beyond abstinence alone Of all MOUD, monthly extended-release buprenorphine (BUP-XR) accounted for the smallest proportion of non-fatal and fatal OD events compared to no treatment.
RICHMOND, Va., April 24, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc. (Nasdaq: INDV), a leader in the treatment of opioid use disorder (OUD), will present one new scientific poster and collaborated with VA Tech on a second poster which will be presented at the American Society of Addiction Medicine (ASAM) Annual Conference, held April 23-26, 2026, in San Diego, California. The data add to the growing body of evidence evaluating extended-release buprenorphine, a monthly injectable commercially available as SUBLOCADE®, in supporting meaningful outcomes for people living with OUD, including overdose-related outcomes and broader indicators associated with recovery.
RICHMOND, Va., April 16, 2026 (GLOBE NEWSWIRE) -- Indivior PLC (Nasdaq: INDV) today announced results from a national survey published in the Journal of Correctional Health Care showing that correctional leaders identify staffing and coordination gaps as key barriers to reducing diversion of medications for opioid use disorder (MOUD) and recognized long-acting injectable (LAI) buprenorphine as a strategy to help mitigate diversion and improve treatment in jail and prison settings.
On April 10, 2026, Indivior Pharmaceuticals Inc (INDV) shares fell 5.5% today, closing at $30.54. The stock has seen a significant fluctuation in its price, wit
The consensus price target hints at a 46% upside potential for Indivior Pharmaceuticals Inc. (INDV). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
RICHMOND, Va., April 09, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc. (Nasdaq: INDV) today announced that it will report its first quarter 2026 financial results on Thursday, April 30, 2026, at 7:00 a.m. U.S. EDT. Following the release of the financial results, Joe Ciaffoni, Chief Executive Officer, and other members of Indivior's leadership team will host a presentation via live webcast at 8:00 a.m. U.S. EDT.
Innovation is at its peak in the Zacks Medical-Drugs industry. INDV, CPRX, TBPH, RLMD and AVTX may prove to be good additions to one's portfolio.
Model estimates SUBLOCADE® may reduce staff time and associated costs compared with other medications for opioid use disorder in jails and prisons RICHMOND, Va., March 31, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc., (Nasdaq: INDV) today announced findings from a new cost impact model published in The Journal of Current Medical Research and Opinion, estimating that the use of extended-release buprenorphine, a monthly injectable commercially available as SUBLOCADE®, may reduce staff time and associated costs in jails and prisons compared with other medications for opioid use disorder (MOUD).
Indivior has rallied over 300% since 2024 lows, driven by Sublocade market share stability, cost controls, and shareholder activism. INDV remains a 'buy' at a $3.7bn market cap, with management targeting 8% Sublocade sales growth in 2026 and 48% adj. EBITDA margins. Valuation is attractive at sub-10x NTM EV/EBITDA and a 10% FCF yield, with a $400m buyback approved for 2026–2027.
INDV, CIEN and UCTT stand out for strong efficiency metrics, passing a rigorous screen that highlights asset use, margins and turnover strength.
Indivior PLC (NASDAQ: INDV - Get Free Report) has received an average recommendation of "Buy" from the seven research firms that are presently covering the firm, MarketBeat reports. One research analyst has rated the stock with a hold recommendation, five have given a buy recommendation and one has issued a strong buy recommendation on the company.
The heavy selling pressure might have exhausted for Indivior Pharmaceuticals Inc. (INDV) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
RICHMOND, Va., March 17, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals Inc. (Nasdaq: INDV) announced results from a cross-sectional survey published in the Journal of Correctional Health Care that reveal critical gaps in the availability of medications for opioid use disorder (MOUD) across U.S. correctional facilities.
RICHMOND, Va., March 12, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc. (Nasdaq: INDV) today announced the pricing of its offering of $450,000,000 aggregate principal amount of 0.625% convertible senior notes due 2031 (the “notes”) in a private offering to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). The offering was upsized from the previously announced offering size of $400,000,000 aggregate principal amount of notes. Indivior also granted the initial purchasers of the notes a 30-day option to purchase up to an additional $50,000,000 principal amount of notes. The sale of the notes to the initial purchasers is expected to settle on March 17, 2026, subject to customary closing conditions.
RICHMOND, Va., March 12, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc. (Nasdaq: INDV) today announced its intention to offer, subject to market and other conditions, $400,000,000 aggregate principal amount of convertible senior notes due 2031 (the “notes”) in a private offering to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). Indivior also expects to grant the initial purchasers of the notes a 30-day option to purchase up to an additional $60,000,000 principal amount of notes.
Patients adherent to SUBLOCADE ® for 12 months had 42% lower adjusted non-MOUD medical costs vs. those adherent to other forms of MOUD Patients adherent to SUBLOCADE had the lowest inpatient, emergency department, and detoxification utilization across all treatment groups RICHMOND, Va.
Intech Investment Management LLC trimmed its position in Indivior PLC (NASDAQ: INDV) by 33.2% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 41,175 shares of the company's stock after selling 20,478 shares during the period. Intech Investment
Indivior PLC (NASDAQ: INDV - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the seven brokerages that are covering the firm, MarketBeat.com reports. One analyst has rated the stock with a hold recommendation and six have given a buy recommendation to the company. The average 1-year target price among analysts that
